$SRAX
SRAX, Inc. Stock $srax

$srax Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000149315222028254 Filed on October 12, 2022

Income Statement

Concept	2022 Q3	2021 Q4	2021
Revenue	$5.309M	$5.275M	$26.71M
YoY Change	-36.14%	16.7%	208.75%
Cost Of Revenue	$942.0K	$1.614M	$6.521M
YoY Change	-47.78%	34.5%	151.78%
Gross Profit	$4.367M	$3.661M	$20.19M
YoY Change	-32.91%	10.27%	233.1%
Gross Profit Margin	82.26%	69.4%	75.58%
Selling, General & Admin	$3.490M	-$67.00K	$11.68M
YoY Change	-54.92%	-101.35%	-28.55%
% of Gross Profit	79.92%	-1.83%	57.87%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$18.00K	-$203.0K	$72.00K
YoY Change	-95.08%	-161.52%	-94.46%
% of Gross Profit	0.41%	-5.54%	0.36%
Operating Expenses	$3.507M	-$347.0K	$11.68M
YoY Change	-56.74%	-106.52%	-33.81%
Operating Profit	$860.0K	$4.008M	-$85.00K
YoY Change	-153.82%	-300.4%	-99.27%
Interest Expense	-$5.763M	-$5.733M	-$19.82M
YoY Change	34.96%	1.47%	80.79%
% of Operating Profit	-670.12%	-143.04%
Other Income/Expense, Net	-$4.679M	$7.990M	-$16.21M
YoY Change	-469.88%	-80000.0%	438.33%
Pretax Income	-$3.819M	$6.265M	-$16.29M
YoY Change	-17.03%	2747.73%	10.99%
Income Tax		-$127.0K	-$127.0K
% Of Pretax Income		-2.03%
Net Earnings	-$3.819M	-$14.10M	-$34.76M
YoY Change	-0.26%	-7522.63%	136.32%
Net Earnings / Revenue	-71.93%	-267.36%	-130.16%
Basic Earnings Per Share	-$0.14		-$1.48
Diluted Earnings Per Share	-$0.14	-$540.7K	-$1.476M
COMMON SHARES
Basic Shares Outstanding	26.32M shares		23.55M shares
Diluted Shares Outstanding	26.34M shares		23.55M shares

Balance Sheet

Concept	2022 Q3	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.24M	$9.210M	$20.89M
YoY Change	-32.15%	3.48%	134.72%
Cash & Equivalents	$116.0K	$1.348M	$1.348M
Short-Term Investments	$21.12M	$7.862M	$19.54M
Other Short-Term Assets	$352.0K	$430.0K	$430.0K
YoY Change	-64.73%	16.22%	16.22%
Inventory
Prepaid Expenses
Receivables	$319.0K	$821.0K	$821.0K
Other Receivables	$499.0K	$844.0K	$844.0K
Total Short-Term Assets	$4.425M	$22.99M	$22.99M
YoY Change	-86.86%	93.64%	93.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$121.0K	$114.0K	$371.0K
YoY Change	-72.5%	-76.25%	-22.71%
Goodwill	$7.706M	$17.91M
YoY Change		0.0%
Intangibles	$0.00	$1.443M
YoY Change		-3.28%
Long-Term Investments	$18.20M
YoY Change
Other Assets	$8.000K	$36.00K	$36.00K
YoY Change	-77.78%
Total Long-Term Assets	$26.20M	$20.69M	$20.69M
YoY Change	-1.66%	-23.76%	-23.76%
TOTAL ASSETS
Total Short-Term Assets	$4.425M	$22.99M	$22.99M
Total Long-Term Assets	$26.20M	$20.69M	$20.69M
Total Assets	$30.63M	$43.68M	$43.68M
YoY Change	-49.22%	11.96%	11.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.10M	$4.095M	$1.938M
YoY Change	156.84%	15.03%	-26.31%
Accrued Expenses		$1.518M	$2.287M
YoY Change		1280.0%	119.9%
Deferred Revenue
YoY Change
Short-Term Debt	$10.00K	$10.00K	$10.00K
YoY Change		-98.67%	-98.67%
Long-Term Debt Due	$1.094M	$1.164M	$1.164M
YoY Change	2.72%	-80.66%	-80.66%
Total Short-Term Liabilities	$31.43M	$22.82M	$22.82M
YoY Change	18.42%	19.83%	19.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$0.00	$114.0K	$114.0K
YoY Change	-100.0%	-52.5%	-52.5%
Total Long-Term Liabilities	$0.00	$114.0K	$114.0K
YoY Change	-100.0%	-81.61%	-81.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.43M	$22.82M	$22.82M
Total Long-Term Liabilities	$0.00	$114.0K	$114.0K
Total Liabilities	$31.43M	$22.93M	$22.93M
YoY Change	-16.03%	15.87%	15.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$53.48M	-$30.36M
YoY Change		-39.7%
Common Stock		$51.10M
YoY Change		-26.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$807.0K	$20.75M	$20.75M
YoY Change
Total Liabilities & Shareholders Equity	$30.63M	$43.68M	$43.68M
YoY Change	-49.22%	11.96%	11.96%

Cashflow Statement

Concept	2022 Q3	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$3.819M	-$14.10M	-$34.76M
YoY Change	-0.26%	-7522.63%	136.32%
Depreciation, Depletion And Amortization	$18.00K	-$203.0K	$72.00K
YoY Change	-95.08%	-161.52%	-94.46%
Cash From Operating Activities	-$1.434M	-$4.765M	-$23.44M
YoY Change	-76.12%	32.36%	73.72%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$229.0K	$69.00K
YoY Change	-100.0%	-32.65%	-105.7%
Acquisitions
YoY Change
Other Investing Activities	$698.0K	$1.073M	$5.706M
YoY Change	-75.18%	-85.77%	-21.3%
Cash From Investing Activities	$698.0K	$844.0K	$4.839M
YoY Change	-73.26%	-88.29%	-20.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$284.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	592.0K	-868.0K	$20.18M
YoY Change	277.07%	-84.5%	156.73%
NET CHANGE
Cash From Operating Activities	-1.434M	-4.765M	-$23.44M
Cash From Investing Activities	698.0K	844.0K	$4.839M
Cash From Financing Activities	592.0K	-868.0K	$20.18M
Net Change In Cash	-144.0K	-4.789M	$1.583M
YoY Change	-95.55%	140.65%	276.9%
FREE CASH FLOW
Cash From Operating Activities	-$1.434M	-$4.765M	-$23.44M
Capital Expenditures	$0.00	-$229.0K	$69.00K
Free Cash Flow	-$1.434M	-$4.536M	-$23.50M
YoY Change	-75.28%	39.14%	91.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	SRAX	Forgiveness Of Payroll Protection Program Loan ForgivenessOfPayrollProtectionProgramLoan		usd
CY2021	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
CY2020	SRAX	Noncontrolling Interest Increase From Warrant Issued NoncontrollingInterestIncreaseFromWarrantIssued		usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2020	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation		usd
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2020	SRAX	Loss On Disposal Of Subsidiary LossOnDisposalOfSubsidiary		usd
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001538217
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q4	SRAX	Contracts Receivable ContractsReceivable		usd
CY2020Q4	SRAX	Designated Assets For Return Of Capital DesignatedAssetsForReturnOfCapital		usd
CY2021Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2021Q4	SRAX	Longterm Assets Of Discontinued Operations LongtermAssetsOfDiscontinuedOperations		usd
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2020	SRAX	Unrealized Loss On Designated Assets UnrealizedLossOnDesignatedAssets		usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2020	SRAX	Gain Loss On Fair Value In Preferred Stock GainLossOnFairValueInPreferredStock		usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest		usd
CY2020	SRAX	Loss On Unrealized Designated Assets LossOnUnrealizedDesignatedAssets		usd
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2020	us-gaap	Interest Income Other InterestIncomeOther		usd
CY2020	SRAX	Gain Loss On Fair Value In Preferred Stock GainLossOnFairValueInPreferredStock		usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2020	SRAX	Marketable Securities Received For Accounts Receivable Previously Written Off MarketableSecuritiesReceivedForAccountsReceivablePreviouslyWrittenOff		usd
CY2020	SRAX	Noncash Financing Expense NoncashFinancingExpense		usd
CY2020	SRAX	Increase Decrease Deferred Revenues IncreaseDecreaseDeferredRevenues		usd
CY2020	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities		usd
CY2020	SRAX	Proceeds From Sale Of Designated Assets ProceedsFromSaleOfDesignatedAssets		usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2021	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects		usd
CY2021	SRAX	Acquisition Of Ld Micro Net Of Cash Acquired AcquisitionOfLdMicroNetOfCashAcquired		usd
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021	SRAX	Proceeds From Oid Notes Payable Less Issuance Costs ProceedsFromOidNotesPayableLessIssuanceCosts		usd
CY2021	SRAX	Redemption Of Oid Notes Payable RedemptionOfOidNotesPayable		usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	SRAX	Repayments Of Short Term Notes Payable RepaymentsOfShortTermNotesPayable		usd
CY2021	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt		usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2020	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2021Q4	SRAX	Cash And Cash Equivalents Discontinued Operations CashAndCashEquivalentsDiscontinuedOperations		usd
CY2020Q4	SRAX	Cash Reserved For Designated Asset For Return Of Capital CashReservedForDesignatedAssetForReturnOfCapital		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2020	SRAX	Designation Of Marketable Securities For Dividend Distribution DesignationOfMarketableSecuritiesForDividendDistribution		usd
CY2020	SRAX	Dividends On Preferred Stock DividendsOnPreferredStock		usd
CY2021	SRAX	Vesting Of Common Stock Award VestingOfCommonStockAward		usd
CY2021	SRAX	Relative Fair Value Of Warrants Issued With Term Loan RelativeFairValueOfWarrantsIssuedWithTermLoan		usd
CY2021	SRAX	Derivative Liabilities Transferred To Equity DerivativeLiabilitiesTransferredToEquity		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2021	SRAX	Shares Of Common Stock Issued For Extension Agreement SharesOfCommonStockIssuedForExtensionAgreement		usd
CY2021	SRAX	Fair Value Of Warrants Issued For Debt Financings FairValueOfWarrantsIssuedForDebtFinancings		usd
CY2021	SRAX	Premium On Debt Financings PremiumOnDebtFinancings		usd
CY2021	SRAX	Original Issue Discount Recorded On Oid Convertible Debentures OriginalIssueDiscountRecordedOnOidConvertibleDebentures		usd
CY2021	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
CY2021	SRAX	Common Stock Issued To Settle Liability CommonStockIssuedToSettleLiability		usd
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration		usd
CY2020	SRAX	Disposal Group Including Discontinued Operation Financing Costs DisposalGroupIncludingDiscontinuedOperationFinancingCosts		usd
CY2021	SRAX	Disposal Group Including Discontinued Operation Realized Loss On Marketable Securities DisposalGroupIncludingDiscontinuedOperationRealizedLossOnMarketableSecurities		usd
CY2020	SRAX	Disposal Group Including Discontinued Operation Impairment Of Goodwill DisposalGroupIncludingDiscontinuedOperationImpairmentOfGoodwill		usd
CY2021	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation		usd
CY2020Q4	SRAX	Contracts Receivable ContractsReceivable		usd
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue1
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2019Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue		usd
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageGrantDateFairValue
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2020	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
CY2020	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2021	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
CY2021Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedInstricticValue		usd
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2021	SRAX	Current Valuation Allowance CurrentValuationAllowance		usd
CY2021	SRAX	Deferred Valuation Allowance DeferredValuationAllowance		usd
CY2021	SRAX	Valuation Allowance Income Tax Benefit Continuing Operations ValuationAllowanceIncomeTaxBenefitContinuingOperations		usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2020	SRAX	Current Valuation Allowance CurrentValuationAllowance		usd
CY2020	SRAX	Deferred Valuation Allowance DeferredValuationAllowance		usd
CY2020	SRAX	Valuation Allowance Income Tax Benefit Continuing Operations ValuationAllowanceIncomeTaxBenefitContinuingOperations		usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		usd
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities		usd
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities		usd
CY2019Q4	SRAX	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets		usd
CY2019Q4	SRAX	Deferred Tax Liabilities Interest Expense Limitation Carryover DeferredTaxLiabilitiesInterestExpenseLimitationCarryover		usd
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure		usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue		usd
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-37916
CY2021	dei	Entity Registrant Name EntityRegistrantName	SRAX, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2925231
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	2629 Townsgate Road #215
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Westlake Village
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91361
CY2021	dei	City Area Code CityAreaCode	(323)
CY2021	dei	Local Phone Number LocalPhoneNumber	694-9800
CY2021	dei	Security12b Title Security12bTitle	Class A Common Stock, $0.001 par value
CY2021	dei	Trading Symbol TradingSymbol	SRAX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	121972024	usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26315178	shares
CY2021	dei	Auditor Name AuditorName	RBSM LLP
CY2021	dei	Auditor Location AuditorLocation	New York, NY
CY2021	dei	Auditor Firm AuditorFirmId	587
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1348000	usd
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	450000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	821000	usd
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1409000	usd
CY2021Q4	SRAX	Contracts Receivable ContractsReceivable	844000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15617000	usd
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8447000	usd
CY2021Q4	SRAX	Designated Assets For Return Of Capital DesignatedAssetsForReturnOfCapital	3925000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	430000	usd
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	361000	usd
CY2020Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1206000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	22985000	usd
CY2020Q4	us-gaap	Assets Current AssetsCurrent	11873000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	935000	usd
CY2020Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	893000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000	usd
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1443000	usd
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1492000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	257000	usd
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	366000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36000	usd
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	17906000	usd
CY2020Q4	us-gaap	Goodwill Goodwill	17906000	usd
CY2020Q4	SRAX	Longterm Assets Of Discontinued Operations LongtermAssetsOfDiscontinuedOperations	6364000	usd
CY2021Q4	us-gaap	Assets Assets	43676000	usd
CY2020Q4	us-gaap	Assets Assets	39013000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4095000	usd
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2708000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	12859000	usd
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	4842000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	763000	usd
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3417000	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	10000	usd
CY2020Q4	us-gaap	Loans Payable Current LoansPayableCurrent	747000	usd
CY2021Q4	SRAX	Oid Convertible Debentures Short Term OidConvertibleDebenturesShortTerm	1164000	usd
CY2020Q4	SRAX	Oid Convertible Debentures Short Term OidConvertibleDebenturesShortTerm	6016000	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	3925000	usd
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1305000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22816000	usd
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19035000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	114000	usd
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	243000	usd
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	379000	usd
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	131000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	22930000	usd
CY2020Q4	us-gaap	Liabilities Liabilities	19788000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	26000	usd
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	16000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	51075000	usd
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	69551000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30355000	usd
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50342000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20746000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19225000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43676000	usd
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39013000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26707000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6479000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16294000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10043000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-127000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.69
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.69
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.79
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.32
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	6521000	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	1789000	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	7533000	usd
CY2020	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4683000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6330000	usd
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1717000	usd
CY2021	SRAX	Platform Costs PlatformCosts	214000	usd
CY2020	SRAX	Platform Costs PlatformCosts	960000	usd
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	842000	usd
CY2020	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	772000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5352000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3590000	usd
CY2021	SRAX	Cost And Operating Expenses CostAndOperatingExpenses	26792000	usd
CY2020	SRAX	Cost And Operating Expenses CostAndOperatingExpenses	13511000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-85000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-7032000	usd
CY2021	SRAX	Financing Costs FinancingCosts	10295000	usd
CY2020	SRAX	Financing Costs FinancingCosts	12150000	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	804000	usd
CY2020	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	684000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-7904000	usd
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	261000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-84000	usd
CY2021	SRAX	Unrealized Loss On Designated Assets UnrealizedLossOnDesignatedAssets	2378000	usd
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	7873000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	42000	usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1144000	usd
CY2021	SRAX	Gain Loss On Fair Value In Preferred Stock GainLossOnFairValueInPreferredStock	2462000	usd
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	321000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-16209000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3011000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-16167000	usd
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10064000	usd
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-14376000	usd
CY2020	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-4641000	usd
CY2021	SRAX	Loss On Disposal Of Subsidiary LossOnDisposalOfSubsidiary	10684000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-25060000	usd
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-4641000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-41227000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-14705000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-16167000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	19225000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	19225000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1006000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	284000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5974000	usd
CY2021	SRAX	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	15952000	usd
CY2021	SRAX	Warrants Issued As Inducement To Exercise Warrants WarrantsIssuedAsInducementToExerciseWarrants	7737000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-6465000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-34762000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-14705000	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	95000	usd
CY2021	SRAX	Noncontrolling Interest Increase From Warrants Issued NoncontrollingInterestIncreaseFromWarrantsIssued	885000	usd
CY2021	SRAX	Noncontrolling Interest Series B Convertible Preferred Stock Issued NoncontrollingInterestSeriesBConvertiblePreferredStockIssued	5860000	usd
CY2021	SRAX	Noncontrolling Interest Increase From Convertible Debt With Conversion Feature NoncontrollingInterestIncreaseFromConvertibleDebtWithConversionFeature	5860000	usd
CY2021	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	6387000	usd
CY2021	SRAX	Disposition Of Subsidiary DispositionOfSubsidiary	6465000	usd
CY2021	SRAX	Repurchase And Retirement Of Shares RepurchaseAndRetirementOfShares	-793000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-34762000	usd
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23550744	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14649788	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	12506000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-6465000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20746000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20746000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-41227000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-14705000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	25060000	usd
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	4641000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1710000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4331000	usd
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	71000	usd
CY2020	SRAX	Shares Issued For Debt Extinguishment SharesIssuedForDebtExtinguishment	181000	usd
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	434000	usd
CY2020	SRAX	Common Stock Issued For Acquisition Of Subsidiary Value CommonStockIssuedForAcquisitionOfSubsidiaryValue	4264000	usd
CY2020	SRAX	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity	4076000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	46000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	6311000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-14705000	usd
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10064000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-7904000	usd
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	261000	usd
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	804000	usd
CY2020	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	684000	usd
CY2021	SRAX	Loss On Unrealized Designated Assets LossOnUnrealizedDesignatedAssets	2378000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-84000	usd
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	7873000	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	42000	usd
CY2021	SRAX	Gain Loss On Fair Value In Preferred Stock GainLossOnFairValueInPreferredStock	2462000	usd
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	321000	usd
CY2021	SRAX	Forgiveness Of Payroll Protection Program Loan ForgivenessOfPayrollProtectionProgramLoan	1116000	usd
CY2021	SRAX	Noncontrolling Interest Increase From Warrant Issued NoncontrollingInterestIncreaseFromWarrantIssued	885000	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1103000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	7737000	usd
CY2021	SRAX	Marketable Securities Received For Accounts Receivable Previously Written Off MarketableSecuritiesReceivedForAccountsReceivablePreviouslyWrittenOff	409000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	854000	usd
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	9128000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1006000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1615000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	17000	usd
CY2021	us-gaap	Depreciation Depreciation	72000	usd
CY2020	us-gaap	Depreciation Depreciation	28000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	847000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	744000	usd
CY2021	SRAX	Net Change In Right Of Use Asset And Liability NetChangeInRightOfUseAssetAndLiability	20000	usd
CY2020	SRAX	Net Change In Right Of Use Asset And Liability NetChangeInRightOfUseAssetAndLiability	19000	usd
CY2021	SRAX	Noncash Financing Expense NoncashFinancingExpense	268000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1680000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1439000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	820000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-400000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3278000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1521000	usd
CY2021	SRAX	Increase Decrease Deferred Revenues IncreaseDecreaseDeferredRevenues	20669000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	350000	usd
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-3049000	usd
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-131000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15317000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9154000	usd
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-8118000	usd
CY2020	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-4335000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23435000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13489000	usd
CY2021	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	8666000	usd
CY2020	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	519000	usd
CY2021	SRAX	Proceeds From Sale Of Designated Assets ProceedsFromSaleOfDesignatedAssets	686000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1450000	usd
CY2020	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	7000000	usd
CY2020	SRAX	Acquisition Of Ld Micro Net Of Cash Acquired AcquisitionOfLdMicroNetOfCashAcquired	697000	usd
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	3004000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	798000	usd
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	633000	usd
CY2021	SRAX	Proceeds From Payments For Acquire Other Assets ProceedsFromPaymentsForAcquireOtherAssets	33000	usd
CY2020	SRAX	Proceeds From Payments For Acquire Other Assets ProceedsFromPaymentsForAcquireOtherAssets	-32000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3998000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	6221000	usd
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	841000	usd
CY2020	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-175000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4839000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6046000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	284000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15952000	usd
CY2021	SRAX	Repurchase Of Shares RepurchaseOfShares	793000	usd
CY2020	SRAX	Proceeds From Oid Notes Payable Less Issuance Costs ProceedsFromOidNotesPayableLessIssuanceCosts	11988000	usd
CY2020	SRAX	Redemption Of Oid Notes Payable RedemptionOfOidNotesPayable	6070000	usd
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	960000	usd
CY2020	SRAX	Repayments Of Short Term Notes Payable RepaymentsOfShortTermNotesPayable	100000	usd
CY2020	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	1084000	usd
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2130000	usd
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2130000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15443000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7862000	usd
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	4736000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20179000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7862000	usd
CY2021	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	4124000	usd
CY2020	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	4929000	usd
CY2021	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-2541000	usd
CY2020	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-4510000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	451000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2034000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	451000	usd
CY2020Q4	SRAX	Cash And Cash Equivalents Discontinued Operations CashAndCashEquivalentsDiscontinuedOperations	1000	usd
CY2021Q4	SRAX	Cash Cash Equivalents And Restricted Cash From Continuing Operations CashCashEquivalentsAndRestrictedCashFromContinuingOperations	2034000	usd
CY2020Q4	SRAX	Cash Cash Equivalents And Restricted Cash From Continuing Operations CashCashEquivalentsAndRestrictedCashFromContinuingOperations	450000	usd
CY2021Q4	SRAX	Cash Reserved For Designated Asset For Return Of Capital CashReservedForDesignatedAssetForReturnOfCapital	-686000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1348000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	450000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	176000	usd
CY2021	SRAX	Common Stock Received In Lieu Of Cash For Account Received CommonStockReceivedInLieuOfCashForAccountReceived	27842000	usd
CY2020	SRAX	Common Stock Received In Lieu Of Cash For Account Received CommonStockReceivedInLieuOfCashForAccountReceived	8406000	usd
CY2021	us-gaap	Notes Reduction NotesReduction	5974000	usd
CY2020	us-gaap	Notes Reduction NotesReduction	434000	usd
CY2021	SRAX	Designation Of Marketable Securities For Dividend Distribution DesignationOfMarketableSecuritiesForDividendDistribution	-6387000	usd
CY2021	SRAX	Dividends On Preferred Stock DividendsOnPreferredStock	6387000	usd
CY2020	SRAX	Vesting Of Common Stock Award VestingOfCommonStockAward	94000	usd
CY2020	SRAX	Relative Fair Value Of Warrants Issued With Term Loan RelativeFairValueOfWarrantsIssuedWithTermLoan	83000	usd
CY2020	SRAX	Derivative Liabilities Transferred To Equity DerivativeLiabilitiesTransferredToEquity	4076000	usd
CY2020	us-gaap	Stock Issued1 StockIssued1	71000	usd
CY2020	SRAX	Shares Of Common Stock Issued For Extension Agreement SharesOfCommonStockIssuedForExtensionAgreement	6311000	usd
CY2020	SRAX	Fair Value Of Warrants Issued For Debt Financings FairValueOfWarrantsIssuedForDebtFinancings	4248000	usd
CY2020	SRAX	Premium On Debt Financings PremiumOnDebtFinancings	46000	usd
CY2020	SRAX	Original Issue Discount Recorded On Oid Convertible Debentures OriginalIssueDiscountRecordedOnOidConvertibleDebentures	1931000	usd
CY2020	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	4264000	usd
CY2020	SRAX	Common Stock Issued To Settle Liability CommonStockIssuedToSettleLiability	181000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1348000	usd
CY2021Q4	SRAX	Issuance Of Acquisition Shares Description IssuanceOfAcquisitionSharesDescription	BIGToken’s issuance of the Acquisition Share and the Exchange caused the Company’s BIGToken common stock holdings to decrease from approximately 66% to approximately 4.99%; Therefore, the Company no longer controlled the operations of BIGToken. Given the Company’s loss of control over the operations of BIGToken, the Company deconsolidated BIGToken, as of December 29, 2021, in accordance with ASC 810 Consolidations
CY2021Q4	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	10684000	usd
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zTvQE8W6QlPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zSG1zxqUqixk">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles accepted in the United States of America (“GAAP”) and requires management of the Company to make estimates and assumptions in the preparation of these consolidated financial statements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The most significant areas that require management judgment and which are susceptible to possible change in the near term include the Company’s revenue recognition, allowance for doubtful accounts and sales credits, valuation of marketable investment securities, stock-based compensation, income taxes, purchase price for acquisition, goodwill, other intangible assets, put rights and valuation of other assets and liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-14376000	usd
CY2020	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-4641000	usd
CY2020Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	75000	usd
CY2020Q1	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	454000	usd
CY2020Q1	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	56000	usd
CY2021Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2021Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	1098000	usd
CY2020Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	200000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	130000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	15000	usd
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zahNcFOLfUCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zk5ApwfmJvQl">Concentration of Credit and Significant Customer Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited with financial institutions within the United States. The balances maintained at these financial institutions are generally more than the Federal Deposit Insurance Corporation insurance limits. The Company has not experienced any loss on these accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had one customer with an accounts receivable balance of approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20211231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z72pAZFeZgXk">11</span>%.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2020, the Company had three customers with accounts receivable balances of approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zKo5f8aV55F3">43.41</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zXiQ3Jo2QNMb">11.60</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z6enNxwDeYFg">10.53</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2021, the Company had no customers that account for a significant percentage of total revenue. For the year ended December 31, 2020, the Company had one customer that accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--ProductOrServiceAxis__custom--RevenueMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z98YAdWWXah1" title="Concentration risk percentage">18.1</span>% of total revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-4570000	usd
CY2021	SRAX	Disposal Group Including Discontinued Operation Financing Costs DisposalGroupIncludingDiscontinuedOperationFinancingCosts	5872000	usd
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	798000	usd
CY2020Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	633000	usd
CY2020	SRAX	Disposal Group Including Discontinued Operation Realized Loss On Marketable Securities DisposalGroupIncludingDiscontinuedOperationRealizedLossOnMarketableSecurities	71000	usd
CY2021	SRAX	Disposal Group Including Discontinued Operation Impairment Of Goodwill DisposalGroupIncludingDiscontinuedOperationImpairmentOfGoodwill	1258000	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	7130000	usd
CY2020	us-gaap	Disposal Group Including Discontinued Operation Other Expense DisposalGroupIncludingDiscontinuedOperationOtherExpense	71000	usd
CY2021	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-14376000	usd
CY2020	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-4641000	usd
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11867520	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15366426	shares
CY2021Q4	SRAX	Disposal Group Including Discontinued Operation Fair Value Of Series D Stock And Common Stock DisposalGroupIncludingDiscontinuedOperationFairValueOfSeriesDStockAndCommonStock	31000	usd
CY2021Q4	SRAX	Carrying Amount Of Noncontrolling Interest Of Bigtoken CarryingAmountOfNoncontrollingInterestOfBigtoken	6045000	usd
CY2021Q4	SRAX	Previous Equity Adjustment Of Noncontrolling Interest PreviousEquityAdjustmentOfNoncontrollingInterest	-12510000	usd
CY2021Q4	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-6434000	usd
CY2021Q4	SRAX	Book Basis Of Investment In Bigtoken BookBasisOfInvestmentInBigtoken	4250000	usd
CY2021Q4	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	-10684000	usd
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	1000	usd
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1199000	usd
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets Current DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent	6000	usd
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent	1000	usd
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Goodwill Noncurrent DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent	5445000	usd
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent	917000	usd
CY2020Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	7569000	usd
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Current DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent	853000	usd
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Other Current Liabilities DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities	452000	usd
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1305000	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	3431000	usd
CY2020	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	2168000	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	1090000	usd
CY2020	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	800000	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	2341000	usd
CY2020	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	1368000	usd
CY2021	SRAX	Disposal Group Including Discontinued Operation Employeerelasted Cost DisposalGroupIncludingDiscontinuedOperationEmployeerelastedCost	2419000	usd
CY2020	SRAX	Disposal Group Including Discontinued Operation Employeerelasted Cost DisposalGroupIncludingDiscontinuedOperationEmployeerelastedCost	3212000	usd
CY2021	SRAX	Disposal Group Including Discontinued Operation Selling And Marketing Expense DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense	1136000	usd
CY2020	SRAX	Disposal Group Including Discontinued Operation Selling And Marketing Expense DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense	958000	usd
CY2021	SRAX	Disposal Group Including Discontinued Operation Platform Cost DisposalGroupIncludingDiscontinuedOperationPlatformCost	1350000	usd
CY2020	SRAX	Disposal Group Including Discontinued Operation Platform Cost DisposalGroupIncludingDiscontinuedOperationPlatformCost	707000	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	530000	usd
CY2020	us-gaap	Disposal Group Including Discontinued Operation Depreciation And Amortization DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization	531000	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	4152000	usd
CY2020	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	530000	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	9587000	usd
CY2020	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	5938000	usd
CY2021	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-7246000	usd
CY2020Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	468000	usd
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	6479000	usd
CY2020	SRAX	Business Acquisitions Pro Forma Cost Of Revenues BusinessAcquisitionsProFormaCostOfRevenues	-1789000	usd
CY2020	SRAX	Business Acquisitions Pro Forma Operating Expenses BusinessAcquisitionsProFormaOperatingExpenses	-11722000	usd
CY2020	SRAX	Business Acquisitions Pro Forma Other Expense BusinessAcquisitionsProFormaOtherExpense	-3011000	usd
CY2020	SRAX	Business Acquisitions Pro Forma Income Tax Expense Benefit BusinessAcquisitionsProFormaIncomeTaxExpenseBenefit	21000	usd
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-10064000	usd
CY2020	SRAX	Additional Principal Percentage AdditionalPrincipalPercentage	0.05	pure
CY2020	SRAX	Employee Related Costs EmployeeRelatedCosts	235000	usd
CY2020Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	454000	usd
CY2021Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	631000	usd
CY2020Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	570000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1000000	usd
CY2021Q4	SRAX	Contracts Receivable ContractsReceivable	844000	usd
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8447000	usd
CY2021	SRAX	Marketable Securities Addition MarketableSecuritiesAddition	34914000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	8666000	usd
CY2021	SRAX	Marketable Securities Designationfor Dividend Distribution MarketableSecuritiesDesignationforDividendDistribution	10790000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	8288000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15617000	usd
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	83000	usd
CY2020	SRAX	Marketable Securities Addition MarketableSecuritiesAddition	8406000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	916000	usd
CY2020	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-874000	usd
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8447000	usd
CY2021	SRAX	Proceed From Sale And Maturity Of Marketable Securities ProceedFromSaleAndMaturityOfMarketableSecurities	8666000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	7862000	usd
CY2021	SRAX	Gain On Marketable Securities GainOnMarketableSecurities	804000	usd
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	472000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	163000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	935000	usd
CY2020Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	893000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	357000	usd
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	285000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	114000	usd
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	117000	usd
CY2021	us-gaap	Depreciation Depreciation	72000	usd
CY2020	us-gaap	Depreciation Depreciation	28000	usd
CY2021	SRAX	Current Principal Balance Fee Percentage CurrentPrincipalBalanceFeePercentage	0.05	pure
CY2021Q4	SRAX	Oid Convertible Debentures Face Amount OIDConvertibleDebenturesFaceAmount	1267000	usd
CY2021Q4	SRAX	Oid Convertible Debentures Discount OIDConvertibleDebenturesDiscount	-103000	usd
CY2021Q4	SRAX	Oid Convertible Debentures Short Term OidConvertibleDebenturesShortTerm	1164000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	163000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	12000	usd
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	29000	usd
CY2021	us-gaap	Lease Cost LeaseCost	175000	usd
CY2020	us-gaap	Lease Cost LeaseCost	192000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	244000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5970000	usd
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5172000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-4527000	usd
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-3680000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1443000	usd
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1492000	usd
CY2021	SRAX	Amortization Of Finite Lived Intangible Assets AmortizationOfFiniteLivedIntangibleAssets	847000	usd
CY2020	SRAX	Amortization Of Finite Lived Intangible Assets AmortizationOfFiniteLivedIntangibleAssets	744000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	632000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	404000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	136000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1172000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	17906000	usd
CY2020Q4	us-gaap	Goodwill Goodwill	17906000	usd
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	7706000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P1Y9M
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2021	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	175000	usd
CY2020	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	192000	usd
CY2020Q4	SRAX	Oid Convertible Debentures Face Amount OIDConvertibleDebenturesFaceAmount	9386000	usd
CY2020Q4	SRAX	Oid Convertible Debentures Discount OIDConvertibleDebenturesDiscount	-3370000	usd
CY2020Q4	SRAX	Oid Convertible Debentures Short Term OidConvertibleDebenturesShortTerm	6016000	usd
CY2021Q4	SRAX	Fair Value Of Preferred Stock FairValueOfPreferredStock	3925000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	257000	usd
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	366000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000	usd
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	109000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	114000	usd
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	243000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	244000	usd
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	352000	usd
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.18	pure
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	259000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25995172	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25995172	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16145778	shares
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	163000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	123000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	286000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	42000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1938000	usd
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1900000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1518000	usd
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	537000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	213000	usd
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	232000	usd
CY2021Q4	SRAX	Accrued Commissions Current AccruedCommissionsCurrent	303000	usd
CY2020Q4	SRAX	Accrued Commissions Current AccruedCommissionsCurrent	32000	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	123000	usd
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	7000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4095000	usd
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2708000	usd
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16145778	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y9M21D
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12859000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4842000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000	usd
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	109000	usd
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	633000	usd
CY2020Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3308000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	763000	usd
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3417000	usd
CY2021	SRAX	Forgiveness Of Payroll Protection Program Loan ForgivenessOfPayrollProtectionProgramLoan	1116000	usd
CY2020Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	300000	usd
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5639000	usd
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1118000	usd
CY2020Q4	SRAX	Increase Decrease In Additional Paid In Capital IncreaseDecreaseInAdditionalPaidInCapital	434000	usd
CY2020Q1	us-gaap	Receivable With Imputed Interest Description ReceivableWithImputedInterestDescription	we agreed to provide a true-up to the purchaser of the receivable of between 10% and 36% depending on the payment date. In the event of nonpayment of the receivables by March 24, 2020 and March 30, 2020, as applicable to the receivables, the purchaser may require us to purchase any outstanding portion of the receivables for 136% of its outstanding balance (“Payment Date”).
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	60000	usd
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0024	pure
CY2020Q2	us-gaap	Share Price SharePrice	1.95
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1192519	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.14
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y2M1D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	766172	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.77
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm	P3Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	521000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.72
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	316367	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.14
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue	3.14
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1642324	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.30
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P2Y9M21D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	844742	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.54
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y7M13D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	333000	usd
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Vested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingVestedWeightedAverageGrantDateFairValue	3.54
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	797582	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.81
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding N Onvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingNOnvestedWeightedAverageRemainingContractualTerm1	P3Y
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInstricticValue	207000	usd
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	2.09
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1642324	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.30
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1331780	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	21627	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.38
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm	P6Y3M14D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	2000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.60
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12500	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.70
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Exercised Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageExercisedRemainingContractualTerm	P3Y7M17D
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageGrantDateFairValue	2.00
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	319671	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.60
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Forfeited Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageForfeitedRemainingContractualTerm	P0Y7M24D
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue	3.49
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.02
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P2Y4M20D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1969000	usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue1	2.13
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	870750	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.05
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y3M7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1265000	usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Vested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingVestedWeightedAverageGrantDateFairValue	2.15
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	461030	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.96
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding N Onvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingNOnvestedWeightedAverageRemainingContractualTerm1	P2Y7M13D
CY2021Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInstricticValue	703000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	2.10
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1006000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1615000	usd
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	811000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	811000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y9M29D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.96	pure
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.11	pure
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.83
CY2021Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4930000	usd
CY2021Q1	SRAX	Number Of Warrants Cancelled NumberOfWarrantsCancelled	349197	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2283171	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	6828611	shares
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	15952000	usd
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6237430	shares
CY2019Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.57
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y8M4D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	7421054	shares
CY2020	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice	2.63
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P1Y9M25D
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodGrantDateIntrinsicValue	3929000
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.38
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	1073201	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	12585283	shares
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.98
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P1Y9M10D
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	4460000	usd
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Grant Date Fair Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageGrantDateFairValue1	1.38
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingNumber	12285283	shares
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.94
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y8M26D
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4460000	usd
CY2020	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Vested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingVestedWeightedAverageGrantDateFairValue	1.38
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedNumberOfShares	300000	shares
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedWeightedAverageGrantDateFairValue	4.75
CY2020	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Nonvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingNonvestedWeightedAverageRemainingContractualTerm1	P3Y4M13D
CY2020Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Instrictic Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedInstricticValue	0	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	12585283	shares
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.98
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y9M10D
CY2020Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	4460000	usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageGrantDateFairValue	1.38
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	4582345	shares
CY2021	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice	7.48
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P0Y1M9D
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.70
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	7148501	shares
CY2021	SRAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice	2.74
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Exercised Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageExercisedRemainingContractualTerm	P0Y9M10D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	10019127	shares
CY2021Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	5.21
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P0Y5M19D
CY2021Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	6779000	usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Grant Date Fair Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageGrantDateFairValue1	1.70
CY2021Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingNumber	9719127	shares
CY2021Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.22
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y4M28D
CY2021Q4	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	6779000	usd
CY2021	SRAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Vested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingVestedWeightedAverageGrantDateFairValue	1.70
CY2021Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedNumberOfShares	300000	shares
CY2021Q4	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsNonvestedWeightedAverageGrantDateFairValue	4.75
CY2021	SRAX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Nonvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingNonvestedWeightedAverageRemainingContractualTerm1	P2Y4M13D
CY2020	SRAX	Effective Income Tax Rate Reconciliation Fair Market Adjustment Derivatives EffectiveIncomeTaxRateReconciliationFairMarketAdjustmentDerivatives	0.000	pure
CY2019	SRAX	Effective Income Tax Rate Reconciliation Fair Market Adjustment Derivatives EffectiveIncomeTaxRateReconciliationFairMarketAdjustmentDerivatives	0.005	pure
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-132000	usd
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-132000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	usd
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	5000	usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	5000	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-132000	usd
CY2021	SRAX	Federal State And Local Tax Expense Benefit Continuing Operations FederalStateAndLocalTaxExpenseBenefitContinuingOperations	-127000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-132000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-127000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	21000	usd
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	21000	usd
CY2020	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	21000	usd
CY2020	SRAX	Federal State And Local Tax Expense Benefit Continuing Operations FederalStateAndLocalTaxExpenseBenefitContinuingOperations	21000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	21000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.000	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.027	pure
CY2020	SRAX	Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences	-0.010	pure
CY2019	SRAX	Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences	-0.134	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.151	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.021	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.000	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.033	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.041	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.008	pure
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001	pure
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10003000	usd
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9040000	usd
CY2020Q4	SRAX	Deferred Tax Assets Tax Deferred Expense Bad Debt Expenses DeferredTaxAssetsTaxDeferredExpenseBadDebtExpenses	33000	usd
CY2019Q4	SRAX	Deferred Tax Assets Tax Deferred Expense Bad Debt Expenses DeferredTaxAssetsTaxDeferredExpenseBadDebtExpenses	136000	usd
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	9000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	525000	usd
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	567000	usd
CY2020Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	220000	usd
CY2019Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	629000	usd
CY2020Q4	SRAX	Deferred Tax Assets Contribution Carryover DeferredTaxAssetsContributionCarryover	5000	usd
CY2019Q4	SRAX	Deferred Tax Assets Contribution Carryover DeferredTaxAssetsContributionCarryover	5000	usd
CY2020Q4	SRAX	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	62000	usd
CY2019Q4	SRAX	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	97000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross	2668000	usd
CY2019Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross	120000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	124000	usd
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	173000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13640000	usd
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10776000	usd
CY2020Q4	SRAX	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	-29000	usd
CY2020Q4	SRAX	Deferred Tax Liabilities Rightofuse Asset DeferredTaxLiabilitiesRightofuseAsset	-66000	usd
CY2019Q4	SRAX	Deferred Tax Liabilities Rightofuse Asset DeferredTaxLiabilitiesRightofuseAsset	-101000	usd
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	455000	usd
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	690000	usd
CY2020Q4	SRAX	Deferred Tax Liabilities Interest Expense Limitation Carryover DeferredTaxLiabilitiesInterestExpenseLimitationCarryover	-59000	usd
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	15000	usd
CY2019Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	17000	usd
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	624000	usd
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	808000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13016000	usd
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9968000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13016000	usd
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9968000	usd
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2996000	usd
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2375000	usd
CY2020	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	which are available to offset future taxable income, of approximately $
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	34933000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	73733000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2020	SRAX	Nol Carryforwards Description NolCarryforwardsDescription	The Company is in the process of analyzing their NOL and has not determined if the company has had any change of control issues that could limit the future use of NOL. NOL carryforwards that were generated after 2017 of approximately $
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	29400000	usd
CY2021Q4	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	1000000	usd
CY2021	SRAX	Deferred Payment Fair Value DeferredPaymentFairValue	960000	usd
CY2021Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	40000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	107000	usd
CY2021Q4	us-gaap	Fair Value Concentration Of Risk Notes Receivable FairValueConcentrationOfRiskNotesReceivable	935000	usd
CY2020Q4	us-gaap	Fair Value Concentration Of Risk Notes Receivable FairValueConcentrationOfRiskNotesReceivable	893000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20386000	usd
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	8447000	usd
CY2021Q4	SRAX	Contracts Receivable ContractsReceivable	844000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3925000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	7963000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	-510000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	1310000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	747000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-981000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	7035000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26707000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6479000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12859000	usd
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4842000	usd

Files In Submission

Name	View Source	Status
0001493152-22-028254-index-headers.html	Edgar Link	pending
0001493152-22-028254-index.html	Edgar Link	pending
0001493152-22-028254.txt	Edgar Link	pending
0001493152-22-028254-xbrl.zip	Edgar Link	pending
ex10-37.htm	Edgar Link	pending
ex10-38.htm	Edgar Link	pending
ex10-39.htm	Edgar Link	pending
ex21-01.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_001.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
srax-20211231.xsd	Edgar Link	pending
srax-20211231_lab.xml	Edgar Link	unprocessable
srax-20211231_cal.xml	Edgar Link	unprocessable
srax-20211231_pre.xml	Edgar Link	unprocessable
srax-20211231_def.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SRAX
SRAX, Inc. Stock $srax

2022 Q3 Form 10-K Financial Statement

#000149315222028254 Filed on October 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRAX SRAX, Inc. Stock $srax

2022 Q3 Form 10-K Financial Statement

#000149315222028254 Filed on October 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRAX
SRAX, Inc. Stock $srax